Novartis Kymriah Car-T Cell Therapy Receives Us Fda Approval To Treat Relapsed Or Refractory Follicular Lymphoma

Novartis Announced The Us Food And Drug Administration (Fda) Has Granted Accelerated Approval For Kymriah (Tisagenlecleucel) For The Treatment Of Adult Patients With Relapsed Or Refractory (R/R) Follicular Lymphoma (Fl) After Two Or More Lines Of Systemic Therapy.In Accordance With The Accelerated Approval Programme, Continued Approval For This Indication May Be Contingent Upon Verification And Description Of Clinical Benefit In Confirmatory Trial(S). Kymriah Is Now Fda Approved In Three Indications And Remains The Only Car-T Cell Therapy Approved In Both Adult And Paediatric Settings."We Are Proud Of Today'S Fda Approval Of A Third Indication For Kymriah. We Hope This Treatment Option That Has The Potential For Long-Lasting Results May Help Break The Unrelenting Cycle Of Treatment For Patients With Follicular Lymphoma,

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!